Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DOVA
Previous Symbol
CUSIPN/A
Phone919-748-5975
Debt
Debt-to-Equity Ratio0.17
Current Ratio7.50
Quick Ratio7.40
Price-To-Earnings
Trailing P/E Ratio-10.34
Forward P/E Ratio-5.51
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.38 per share
Price / Book6.08
Profitability
EPS (Most Recent Fiscal Year)($1.40)
Net Income$-29,950,000.00
Net MarginsN/A
Return on Equity-63.82%
Return on Assets-50.15%
Miscellaneous
Employees33
Outstanding Shares28,200,000
Market Cap$408.39 million
OptionableOptionable
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its earnings results on Thursday, November, 8th. The company reported ($0.69) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.81) by $0.12. The business had revenue of $2.93 million for the quarter, compared to analysts' expectations of $2.66 million. View Dova Pharmaceuticals' Earnings History.
When is Dova Pharmaceuticals' next earnings date?
What price target have analysts set for DOVA?
4 Wall Street analysts have issued 1 year price targets for Dova Pharmaceuticals' stock. Their forecasts range from $29.00 to $44.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 148.6% from the stock's current price. View Analyst Price Targets for Dova Pharmaceuticals.
What is the consensus analysts' recommendation for Dova Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dova Pharmaceuticals.
What are Wall Street analysts saying about Dova Pharmaceuticals stock?
Here are some recent quotes from research analysts about Dova Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. " (10/30/2018)
- 2. Jefferies Financial Group Inc analysts commented, "About 6 weeks into Doptelet launch, DOVA has been pleased with reimbursement levels (not seeing pushback from payers); plans to provide some key metrics, including % Rx getting reimbursed by payers on 2Q18 call." (7/15/2018)
Has Dova Pharmaceuticals been receiving favorable news coverage?
Headlines about DOVA stock have been trending very positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 3.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the company's share price in the near future.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include The Medicines (MDCO), Cambrex (CBM), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE), Esperion Therapeutics (ESPR), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Mirati Therapeutics (MRTX) and Tricida (TCDA).
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Mr. Alexander C. Sapir, Pres, CEO & Director (Age 51)
- Dr. Lee F. Allen, Chief Medical Officer (Age 66)
- Mr. Mark W. Hahn, CFO & Sec. (Age 55)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 40)
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Who are Dova Pharmaceuticals' major shareholders?
Dova Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (6.52%), BlackRock Inc. (4.09%), Nexthera Capital LP (3.64%), Vanguard Group Inc. (2.20%), Wells Fargo & Company MN (0.95%) and Fosun International Ltd (0.93%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.
Which institutional investors are selling Dova Pharmaceuticals stock?
Which institutional investors are buying Dova Pharmaceuticals stock?
DOVA stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Sphera Funds Management LTD., Candriam Luxembourg S.C.A., GSA Capital Partners LLP, GW&K Investment Management LLC, Birchview Capital LP, Vanguard Group Inc. and Russell Investments Group Ltd.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $14.48.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $408.39 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.
What is Dova Pharmaceuticals' official website?
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
